NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Surely there are obvious reasons why the company would want to take the DCVax-L trial out to the very end?


Shown: Nivolumab compared to Docetaxel in NSCLC - PFS advantage
At first, Nivo (red line) wasn't doing as well, there was no real difference at the beginning, then the treatment actually became worse than the control (in the graph, lol), and then there's that prolonged, PFS advantage... likely due to pseudo-progression.

Minute 47:33

Public Workshop: Oncology Clinical Trials in the Presence of Non-Proportional Hazards
Feb 5, 2018

It's possible we'll see something like this with the PFS chart in this trial - possible, although not whatsoever certain; and for the OS chart, we could see a very slight separation of the two arms in the beginning, with a more dramatic separation between the two coming later... that is, of course, if there is an advantage to taking DCVax 3 months after surgery vs. upon real progression (which is likely what happened with the control arm).

Given that, surely you can appreciate why they may have pushed out the results, and that -- given they would have pushed the trial out to improve the efficacy and success of the results -- they will want to release those results as soon as they are given the green light by their highly qualified advisory team (the SAB and steering committee).